Trial record 1 of 2 for:
Triheptanoin | Huntington+Disease
A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease (TRIHEP3)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02453061 |
Recruitment Status :
Completed
First Posted : May 25, 2015
Last Update Posted : August 25, 2021
|
Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Collaborator:
Ultragenyx Pharmaceutical Inc
Information provided by (Responsible Party):
Institut National de la Santé Et de la Recherche Médicale, France
Tracking Information | |||
---|---|---|---|
First Submitted Date ICMJE | May 12, 2015 | ||
First Posted Date ICMJE | May 25, 2015 | ||
Last Update Posted Date | August 25, 2021 | ||
Actual Study Start Date ICMJE | June 29, 2015 | ||
Actual Primary Completion Date | December 3, 2019 (Final data collection date for primary outcome measure) | ||
Current Primary Outcome Measures ICMJE |
|
||
Original Primary Outcome Measures ICMJE | Same as current | ||
Change History | |||
Current Secondary Outcome Measures ICMJE |
|
||
Original Secondary Outcome Measures ICMJE | Same as current | ||
Current Other Pre-specified Outcome Measures | Not Provided | ||
Original Other Pre-specified Outcome Measures | Not Provided | ||
Descriptive Information | |||
Brief Title ICMJE | A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease | ||
Official Title ICMJE | A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease | ||
Brief Summary | In the study the investigators plan to include 100 early affected HD patients (5 ≤ UHDRS ≤ 40) in a randomized, double-blind, controlled study in 2 centers (France and the Netherlands). Patients will receive either triheptanoin at 1g/kg of body weight per day (n = 50), or a control oil (n = 50) at 1g/kg of body weight per day for 6 months followed by an open label phase using triheptanoin for another 6 months. Efficacy of triheptanoin will be evaluated by measurements of caudate volume using volumetric magnetic resonance imaging and brain energy metabolism as evaluated by the ratio of inorganic phosphate/phosphocreatine, during visual stimulation, using 31P-MRS. Clinical improvement will be evaluated by UHDRS, TFC, and PBA-S scores as well as performance on the neuropsychological battery; patient quality of life will be evaluated with qualitative research methods after 6 months and with the SF-36 questionnaire before and after treatment; biological tolerance and compliance will be evaluated by routine biochemical blood tests, plasma and urine measurements of triheptanoin oil derivatives and patient report. | ||
Detailed Description | Not Provided | ||
Study Type ICMJE | Interventional | ||
Study Phase ICMJE | Phase 2 | ||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
||
Condition ICMJE | Huntington Disease | ||
Intervention ICMJE |
|
||
Study Arms ICMJE |
|
||
Publications * | Rodrigues FB, Ferreira JJ, Wild EJ. Huntington's Disease Clinical Trials Corner: June 2019. J Huntingtons Dis. 2019;8(3):363-371. doi: 10.3233/JHD-199003. | ||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||
Recruitment Information | |||
Recruitment Status ICMJE | Completed | ||
Actual Enrollment ICMJE |
100 | ||
Original Estimated Enrollment ICMJE | Same as current | ||
Actual Study Completion Date ICMJE | December 3, 2019 | ||
Actual Primary Completion Date | December 3, 2019 (Final data collection date for primary outcome measure) | ||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||
Sex/Gender ICMJE |
|
||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||
Accepts Healthy Volunteers ICMJE | No | ||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||
Listed Location Countries ICMJE | France, Netherlands | ||
Removed Location Countries | |||
Administrative Information | |||
NCT Number ICMJE | NCT02453061 | ||
Other Study ID Numbers ICMJE | C14-62 | ||
Has Data Monitoring Committee | No | ||
U.S. FDA-regulated Product | Not Provided | ||
IPD Sharing Statement ICMJE | Not Provided | ||
Current Responsible Party | Institut National de la Santé Et de la Recherche Médicale, France | ||
Original Responsible Party | Same as current | ||
Current Study Sponsor ICMJE | Institut National de la Santé Et de la Recherche Médicale, France | ||
Original Study Sponsor ICMJE | Same as current | ||
Collaborators ICMJE | Ultragenyx Pharmaceutical Inc | ||
Investigators ICMJE | Not Provided | ||
PRS Account | Institut National de la Santé Et de la Recherche Médicale, France | ||
Verification Date | August 2021 | ||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |